In recent years, advances in diagnostic methods, including computed tomography (CT) and various plasma tumor biomarkers, including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), Cytokeratin 19 fragment (CYFRA21-1) and Neurospecific enolase (NSE), have greatly contributed to the diagnosis and progression assessment of lung carcinoma [2]. This evidence concerns the gene CEACAM5 and lung carcinoma.